221638-74-0

Usage

Uses

Used in Pharmaceutical Industry:
2-(CHLOROMETHYL)-6-NITRO-1,3-BENZOXAZOLE is used as a key intermediate in the synthesis of various pharmaceuticals for its potential medicinal properties. Its unique structure allows for the development of new drugs with improved therapeutic effects and reduced side effects.
Used in Agrochemical Industry:
In the agrochemical industry, 2-(CHLOROMETHYL)-6-NITRO-1,3-BENZOXAZOLE is used as a building block in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can enhance their effectiveness in controlling pests and weeds, leading to increased crop yields and better agricultural productivity.
Used in Organic Chemistry Research:
2-(CHLOROMETHYL)-6-NITRO-1,3-BENZOXAZOLE is utilized as a versatile building block in the synthesis of more complex organic molecules. Its unique functional groups, such as the chloromethyl and nitro groups, enable the formation of various chemical bonds and reactions, making it a valuable tool for organic chemists in the development of new compounds and materials.
Used in the Synthesis of Biologically Active Compounds:
Due to its various biological activities, 2-(CHLOROMETHYL)-6-NITRO-1,3-BENZOXAZOLE is used as a starting material in the synthesis of biologically active compounds. These compounds can be further explored for their potential applications in medicine, such as antimicrobial, antiviral, or anti-inflammatory agents, contributing to the discovery of new therapeutic agents.

Upstream product

• 79-04-9 chloroacetyl chloride 
• 121-88-0 5-Nitro-2-aminophenol 
• 74974-54-2 2-chloro-1,1,1-trimethoxyethane 
• 99-57-0 2-hydroxy-5-nitroaniline 
• 70737-12-1 methyl 2-chloroacetimidate hydrochloride 

Relevant academic research and scientific papers

COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

Indoline -1H- pyrazolo [3,4-d] pyrimidinone compound, as well as preparation method and application thereof

The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, thereof, which may be better selective Wee1 as a new generation, selective inhibitor Wee1 with respect to the existing, inhibitor Wee1 for, Kinase more safe

Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors

A novel series of methyl indolinone-6-carboxylates bearing an indole moiety were identified as potent angiokinase inhibitors. The most active compound, A8, potently targeted the kinase activities of vascular endothelial growth factor receptors 2 and 3, and platelet-derived growth factor receptors α and β, with IC50 values in the nanomolar range. In addition, A8 effectively suppressed the proliferation of human umbilical vein endothelial cells, and HT-29 and MCF-7 cancer cells, by inducing apoptosis. Compound A8 is thus a promising candidate for further investigation.

BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to β-ketoamide compounds of general formula (I) wherein the groups and radicals A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the designations cited in patent claim 1. The invention also relates to medicaments containing at least one inventive amide. As a result of the MCH receptor antagonistic activity, the inventive medicaments are suitable for treating metabolic disorders and/or eating disorders, especially adipositas, bulimia, anorexia, hyperphagia and diabetes.

Beta-ketoamide compounds with MCH antagonistic activity

Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.